Guangzhou Fineimmune Biotechnology Co., Ltd.
Clinical trials sponsored by Guangzhou Fineimmune Biotechnology Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take on Hard-to-Treat cancers Results expected Apr 2027 (estimated)
-
Supercharged immune cells take on advanced liver cancer
Disease control Recruiting nowThis early-phase trial is testing a new treatment called Super CAR-T for people with advanced hepatocellular carcinoma, a type of liver cancer that has spread. The treatment involves taking a patient's own immune cells, modifying them to better recognize and attack cancer cells, …
Phase 1 • Sponsor: Guangzhou FineImmune Biotechnology Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new cell therapy called Super1 TCR-T in 15 people with advanced solid tumors (sarcoma, lung cancer, or melanoma) that have not responded to first-line treatment. The therapy involves taking a patient's own immune cells, genetically modifying them to…
Phase 1 • Sponsor: Guangzhou FineImmune Biotechnology Co., LTD. • Aim: Disease control
Last updated Jun 26, 2026 13:03 UTC